Randomized phase 1b/3 study of erlotinib plus ramucirumab in first-line EGFR mut 1 stage IV NSCLC: phase 1b safety results

被引：0
|
作者：
Nakagawa, K. [1 ]
Garon, E. B. [2 ]
Paz-Ares, L. [3 ]
Ponce, S. [3 ]
Corral Jaime, J. [4 ]
Juan Vidal, O. [5 ]
Nadal, E. [6 ]
Kiura, K. [7 ]
He, S. [8 ]
Treat, J. [8 ]
Dalal, R. [9 ]
Lee, P. [9 ]
Reck, M. [10 ]
Novello, S. [11 ]
机构：
[1] Kinki Univ, Sch Med, Osaka, Japan
[2] UCLA Med Ctr, Santa Monica, CA USA
[3] Hosp Doce Octubre, Madrid, Spain
[4] Hosp Virgen del Rocio, Seville, Spain
[5] Hosp Univ La Fe, Valencia, Spain
[6] Inst Catala Oncol, Barcelona, Spain
[7] Okayama Univ Hosp, Kita Ku, Okayama, Japan
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
[9] Eli Lilly & Co, Bridgewater, MA USA
[10] German Ctr Lung Res DZL, ARCN, Lungen Clin Grosshansdorf, Grosshansdorf, Germany
[11] Eli Lilly Italia SpA, Sesto Fiorentino, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E6
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC
    Camidge, D. Ross
    Barlesi, Fabrice
    Goldman, Jonathan W.
    Morgensztern, Daniel
    Heist, Rebecca
    Vokes, Everett
    Angevin, Eric
    Hong, David S.
    Rybkin, Igor I.
    Barve, Minal
    Bauer, Todd M.
    Delmonte, Angelo
    Dunbar, Martin
    Motwani, Monica
    Parikh, Apurvasena
    Noon, Elysa
    Wu, Jun
    Blot, Vincent
    Kelly, Karen
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (01):
  • [22] First-line avelumab plus axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
    Kudo, Masatoshi
    Motomura, Kenta
    Wada, Yoshiyuki
    Inaba, Yoshitaka
    Sakamoto, Yasunari
    Kurosaki, Masayuki
    Umeyama, Yoshiko
    Kamei, Yoichi
    Yoshimitsu, Junichiro
    Fujii, Yosuke
    Aizawa, Mana
    Robbins, Paul B.
    Furuse, Junji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] Preliminary Results of a Phase 1b Study of Fruquintinib Plus Sintilimab in Advanced Colorectal Cancer
    Bekaii-Saab, Tanios S.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (09) : 8 - 8
  • [24] Phase 1b/2 study results for masitinib plus irinotecan in second-line treatment of esophagogastric adenocarcinoma
    Zaanan, A.
    Bennouna, J.
    Hiret, S.
    Douillard, J. Y.
    Bouche, O.
    Tougeron, D.
    Lecomte, T.
    Ezenfis, J.
    Lepere, C.
    Mansfield, C.
    Moussy, A.
    Dubreuil, P.
    Hermine, O.
    Taieb, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S451 - S451
  • [25] Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results
    Jaeger, Ulrich
    Worel, Nina
    McGuirk, Joseph P.
    Riedell, Peter A.
    Fleury, Isabelle
    Du, Yan
    Han, Xia
    Pearson, David
    Redondo, Santiago
    Waller, Edmund K.
    [J]. BLOOD ADVANCES, 2023, 7 (11) : 2283 - 2286
  • [26] A phase 1b/2 study of ramucirumab in combination with emibetuzumab in patients with advanced solid tumors
    Bendell, Johanna
    Fuchs, Charles
    Voss, Martin
    Bauer, Todd M.
    Choueiri, Toni K.
    Drilon, Alexander
    Thorn, Katharine
    Wijayawardana, Sameera
    Moser, Brian
    Urunuela, Arantxa
    Wacheck, Volker
    Harding, James J.
    [J]. CANCER RESEARCH, 2017, 77
  • [27] A phase 1b study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma
    Finn, Richard
    Ikeda, Masafumi
    Zhu, Andrew
    Sung, Max W.
    Baron, Ari D.
    Kudo, Masatoshi
    Okusaka, Takuji
    Kobayashi, Masahiro
    Kumada, Hiromitsu
    Kaneko, Shuichi
    Pracht, Marc
    Mamontov, Konstantin
    Meyer, Tim
    Mody, Kalgi
    Kubota, Tomoki
    Dutcus, Corina E.
    Saito, Kenichi
    Siegel, Abby B.
    Dubrovsky, Leonid
    Llovet, Josep M.
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S120 - S121
  • [28] Results of the safety and tolerability of ivaltinostat plus capecitabine in the phase 1b portion of a phase 1b/2, dose-escalation, randomized, multi-center study in the maintenance (maint) setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).
    Walker, Evan Justin
    Fountzilas, Christos
    Borazanci, Erkut Hasan
    Shields, Anthony F.
    D'Olimpio, James Thomas
    Hecht, J. Randolph
    Tang, Shou-Ching
    Michelson, Glenn
    Liganor, Lorna
    Cho, Sangsook Ahn
    Ko, Andrew H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 666 - 666
  • [29] Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
    Belada, David
    Kopeckova, Katerina
    Burgues, Juan Miguel Bergua
    Stevens, Don
    Andre, Marc
    Persona, Ernesto Perez
    Pichler, Petra
    Staber, Philipp B.
    Trneny, Marek
    Duell, Johannes
    Waldron-Lynch, Maeve
    Wagner, Steve
    Mukhopadhyay, Amitava
    Dirnberger-Hertweck, Maren
    Burke, John M.
    Nowakowski, Grzegorz S.
    [J]. BLOOD, 2023, 142 (16) : 1348 - 1358
  • [30] A Phase 1b Trial of the Combination of Capecitabine and Erlotinib in Advanced Lung Cancer
    Kumar, Rajiv
    Lo, Karl
    Minchom, Anna R.
    Sharp, Adam
    Davidson, Michael
    Gunapala, Ranga
    Yap, Timothy
    Bhosle, Jaishree
    Popat, Sanjay
    O'Brien, Mary E. R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S547 - S548
12345